Lakefront Biotherapeutics NV (GLPGN) Stock Statistics & Valuation Metrics

Lakefront Biotherapeutics NV has a market cap or net worth of $30.26B. The enterprise value is -$394.90.

Lakefront Biotherapeutics NV has 65,897,070 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lakefront Biotherapeutics NV’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 14.43%.

The current PE Ratio of Lakefront Biotherapeutics NV is 3.2. Lakefront Biotherapeutics NV’s PEG ratio is 0.02.

In the last 12 months, Lakefront Biotherapeutics NV had revenue of 1.11B and earned 320.88M in profits. Earnings per share was 4.87.

In the last 12 months, operating cash flow was -292.39M and capital expenditures -8.73M, giving a free cash flow of -301.12M billion.

Lakefront Biotherapeutics NV pays an annual dividend of ―, resulting in a dividend yield of ―

Lakefront Biotherapeutics NV upcoming earnings date is Nov 12, 2026, After Close (Confirmed).

Lakefront Biotherapeutics NV as a current ratio of 20.15, with Debt / Equity ratio of 0.20%

In the past 12 months, Lakefront Biotherapeutics NV has paid -18.62M in taxes.

Lakefront Biotherapeutics NV EV to EBITDA ratio is 3.38, with an EV/FCF ratio of -8.37.

Lakefront Biotherapeutics NV has $2.98B in cash and marketable securities with $6.43M in debt, giving a net cash position of $2.98B billion.

Gross margin is 98.01%, with operating margin of 42.23%, and net profit margin of 28.85%.

The average price target for Lakefront Biotherapeutics NV is $492.49, which is 11.43% higher than the current price. The consensus rating is Moderate Sell